Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Desvenlafaxine and Paroxetine on Desipramine PK
NCT00329147Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of desvenlafaxine in major depressive disorder (MDD) (2 arms), sponsored by Pfizer. Primary endpoint: Pharmacokinetics of Desipramine at Day 6. Started May 2006; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00329147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329147.